<SEC-DOCUMENT>0001415889-21-003512.txt : 20210706
<SEC-HEADER>0001415889-21-003512.hdr.sgml : 20210706
<ACCEPTANCE-DATETIME>20210706171910
ACCESSION NUMBER:		0001415889-21-003512
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210701
FILED AS OF DATE:		20210706
DATE AS OF CHANGE:		20210706

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Morrone Louis H.
		CENTRAL INDEX KEY:			0001867666

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-02189
		FILM NUMBER:		211075141

	MAIL ADDRESS:	
		STREET 1:		100 ABBOTT PARK ROAD
		CITY:			ABBOTT PARK
		STATE:			IL
		ZIP:			60064

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABBOTT LABORATORIES
		CENTRAL INDEX KEY:			0000001800
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				360698440
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		100 ABBOTT PARK ROAD
		CITY:			ABBOTT PARK
		STATE:			IL
		ZIP:			60064-3500
		BUSINESS PHONE:		2246676100

	MAIL ADDRESS:	
		STREET 1:		100 ABBOTT PARK ROAD
		CITY:			ABBOTT PARK
		STATE:			IL
		ZIP:			60064-3500
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3-07062021_020729.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-07-01</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000001800</issuerCik>
        <issuerName>ABBOTT LABORATORIES</issuerName>
        <issuerTradingSymbol>ABT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001867666</rptOwnerCik>
            <rptOwnerName>Morrone Louis H.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>100 ABBOTT PARK ROAD</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>ABBOTT PARK</rptOwnerCity>
            <rptOwnerState>IL</rptOwnerState>
            <rptOwnerZipCode>60064</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>SENIOR VICE PRESIDENT</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common shares without par value</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>34465</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common shares without par value</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2268</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>Profit Sharing Trust</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Option (right to buy)</value>
                <footnoteId id="F2"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>48.34</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2018-07-10</value>
            </exerciseDate>
            <expirationDate>
                <value>2027-07-09</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>29965</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Option (right to buy)</value>
                <footnoteId id="F3"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>59.94</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2019-02-16</value>
            </exerciseDate>
            <expirationDate>
                <value>2028-02-15</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>51559</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Option (right to buy)</value>
                <footnoteId id="F4"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>75.90</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2020-02-22</value>
            </exerciseDate>
            <expirationDate>
                <value>2029-02-21</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>38190</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Option (right to buy)</value>
                <footnoteId id="F5"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>87.72</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2021-02-21</value>
            </exerciseDate>
            <expirationDate>
                <value>2030-02-20</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>35469</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Option (right to buy)</value>
                <footnoteId id="F6"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>124.04</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2022-02-19</value>
            </exerciseDate>
            <expirationDate>
                <value>2031-02-18</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>22272</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Balance in the Abbott Laboratories Stock Retirement Trust as of July 1, 2021.</footnote>
        <footnote id="F2">Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 9,989 on July 10, 2018, 9,988 on July 10, 2019, and 9,988 on July 10, 2020.</footnote>
        <footnote id="F3">Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 17,187 on February 16, 2019 and 17,186 on February 16, 2020, and an increment of 17,186 becomes exercisable on February 16, 2021.</footnote>
        <footnote id="F4">Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 12,730 on February 22, 2020 and 12,730 on February 22, 2021, and an increment of 12,730 becomes exercisable on February 22, 2022.</footnote>
        <footnote id="F5">Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 11,823 on February 21, 2021 and annual increments of 11,823 become exercisable on each of February 21, 2022 and February 21, 2023.</footnote>
        <footnote id="F6">Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,424 on February 19, 2022,  7,424 on February 19, 2023 and 7,424 on February 19, 2024.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact</signatureName>
        <signatureDate>2021-07-06</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>ex24-07062021_020729.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>32L Timeline</title><meta name="author" content="Abbott Laboratories"><meta name="date" content="07/06/2021"></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px; font-size:12pt"><b>EX 24.1</b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px; font-size:12pt" align="center"><b><u>POWER OF ATTORNEY</u></b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; text-indent:48px; font-size:12pt">The undersigned constitutes and appoints HUBERT L. ALLEN, JESSICA H. PAIK, and AARON N. RICE, and each of them individually, as the undersigned&#146;s true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned&#146;s name, place and stead, to prepare and sign any and all Securities and Exchange Commission (&#147;SEC&#148;) Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, including a Form ID and any other documents necessary to obtain codes and passwords necessary to make electronic filings, and any amendments to such forms, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin:0px"><br></p>
<p style="margin:0px; text-indent:48px; font-size:12pt">A copy of this power of attorney shall be filed with the SEC. &nbsp;The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; font-size:12pt">Date: &nbsp;June 7, 2021</p>
<p style="margin:0px"><br></p>
<p style="margin:0px; padding-left:336px; font-size:12pt"><u>/s/ Louis H. Morrone</u></p>
<p style="margin:0px; padding-left:336px; font-size:12pt">Signature of Reporting Person</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; padding-left:336px; font-size:12pt">Louis H. Morrone</p>
<p style="margin:0px; padding-left:336px; font-size:12pt">Abbott Laboratories</p>
<p style="margin:0px; padding-left:336px; font-size:12pt">100 Abbott Park Road</p>
<p style="margin:0px; padding-left:336px; font-size:12pt">Abbott Park, IL 60064</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br><br><br></p>
<a name="_iDocIDFieldf55c81fc-0cf3-4d50-8790-ebd8"></a><p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
